The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans.
Frank W Weathers, Michelle J Bovin, Daniel J Lee...
https://pubmed.ncbi.nlm.nih.gov/28493729/Actively Recruiting
Led by The University of Texas at Dallas · Updated on 2026-08-20
330
Participants Needed
3
Research Sites
N/A
Total Duration
Researchers are evaluating the benefits of combining repetitive Transcranial Magnetic Stimulation rTMS with Cognitive Processing Therapy CPT to treat combat-related Posttraumatic Stress Disorder PTSD symptoms. The study aims to compare PTSD symptom reduction among three groups those receiving rTMS before CPT sessions, those receiving sham rTMS before CPT, and those receiving rTMS alone. Additionally, the study will assess changes in depression, psychosocial functioning, and brain activity using EEG and MRI. Participants will be randomly assigned to one of three treatment groups 1 30 minutes of sham rTMS to the right dorsolateral prefrontal cortex rDLPFC before each of 12 CPT sessions, 2 30 minutes of active 1 Hz rTMS to the rDLPFC before each of 12 CPT sessions, or 3 30 minutes of active 1 Hz rTMS alone once weekly for 12 weeks. The rTMS device delivers magnetic pulses targeting specific brain regions to potentially influence PTSD symptoms. Participants will undergo assessments at baseline, during treatment sessions 5 and 9, and at 1, 6, and 12 months after treatment completion. These evaluations include PTSD symptom severity measures, neuropsychological tests, EEG recordings, and MRI scans. Researchers will monitor treatment effects and safety throughout the study, which lasts up to 12 months post-treatment.
CONDITIONS
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
E
Elizabeth "Ellen" Morris, PhD
J
Jill Ritter, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The University of Texas at Dallas
Lead Sponsor
University of Texas Southwestern Medical Center
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Active rTMS + CPT | Sham rTMS + CPT | Active rTMS alone | CPT alone |
|---|---|---|---|---|
| What it is | Combination of repetitive transcranial magnetic stimulation (rTMS) plus Cognitive Processing Therapy, as tested in the trial | Sham rTMS paired with Cognitive Processing Therapy, as tested in the trial | Active rTMS alone, without accompanying psychotherapy, as tested in the trial | Cognitive Processing Therapy alone, a trauma‑focused psychotherapy recommended by VA/DoD PTSD guideline |
| Role in trial | Investigational arm combining active rTMS with CPT | Control arm receiving sham rTMS plus CPT | Arm testing active rTMS without psychotherapy | Not included in trial, represents current guideline‑recommended psychotherapy |
| Primary use | Potential to enhance PTSD treatment by combining neuromodulation with trauma‑focused therapy | Control condition accounting for placebo effect of rTMS when combined with CPT | Assessment of rTMS effect in isolation, without CPT | Serves as benchmark psychotherapy known to be effective for PTSD |
| How it is given or performed | Active rTMS delivered to right DLPFC at 1 Hz plus 12 sessions of CPT | Sham rTMS delivered over right prefrontal region with sham coil plus CPT sessions | Active rTMS alone delivered to right DLPFC at 1 Hz | 12 sessions of manualized Cognitive Processing Therapy |
| Evidence status | Efficacy under investigation; no published results yet | Control condition for internal comparison; not evaluated as standalone treatment | Treatment effect under evaluation; no standalone efficacy established | Strong evidence supports CPT’s effectiveness for PTSD as per VA/DoD guideline |
| Important risks | Not yet established from trial; safety profile uncertain | Risks of sham rTMS are procedural, not active magnetic stimulation | Safety under investigation; unknown in this PTSD context | Psychotherapy considered low‑risk compared with device interventions |
| Important limitations | No results yet; unknown if combining rTMS with CPT improves outcomes | Sham control may not account for combined CPT effect alone | Unclear whether rTMS without psychotherapy provides lasting benefit | CPT alone may not be sufficient for all patients; response varies |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Approximately 12 weeks
Participants receive one of three interventions: active rTMS plus Cognitive Processing Therapy, sham rTMS plus Cognitive Processing Therapy, or active rTMS alone over 12 sessions.
12 therapy sessions scheduled weekly
Duration - 12 months post-treatment
Participants complete assessments of PTSD symptoms, depression, psychosocial functioning, EEG, and MRI at 1, 6, and 12 months after treatment to monitor changes and safety.
3 follow-up visits
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Frank W Weathers, Michelle J Bovin, Daniel J Lee...
https://pubmed.ncbi.nlm.nih.gov/28493729/Michelle J Bovin, Shimrit K Black, Paola Rodriguez...
https://pubmed.ncbi.nlm.nih.gov/29723024/A John Rush, Madhukar H Trivedi, Hicham M Ibrahim...
https://pubmed.ncbi.nlm.nih.gov/12946886/Gail D Tillman, Timothy A Kimbrell, Clifford S Calley...
https://pubmed.ncbi.nlm.nih.gov/21304137/Bambi L DeLaRosa, Jeffrey S Spence, Scott K M Shakal...
https://pubmed.ncbi.nlm.nih.gov/25222294/Mandy J Maguire, Matthew R Brier, Patricia S Moore...
https://pubmed.ncbi.nlm.nih.gov/19773108/Clifford S Calley, Michael A Motes, H-Sheng Chiang...
https://pubmed.ncbi.nlm.nih.gov/22451240/S A Montgomery, M Asberg
https://pubmed.ncbi.nlm.nih.gov/444788/Candice M Monson, Paula P Schnurr, Patricia A Resick...
https://pubmed.ncbi.nlm.nih.gov/17032094/T M Keane, J M Caddell, K L Taylor
https://pubmed.ncbi.nlm.nih.gov/3346454/The University of Texas at Dallas
Lead Sponsor
University of Texas Southwestern Medical Center
Collaborating Sponsor